Form 8.5 (EPT/RI)-Renalytix Plc
Renalytix AI Reduces Debt With New Share Issue
Renalytix RNLX Steno Deal; CNS Pharmaceuticals CNSP NASDAQ Compliance
H.C. Wainwright Maintains Renalytix(RNLX.US) With Buy Rating, Maintains Target Price $3
Renalytix Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Buy Rating Justified by Renalytix AI's European Expansion and Positive Medicare Coverage
HC Wainwright & Co. Reiterates Buy on Renalytix, Maintains $3 Price Target
Renalytix Analyst Ratings
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Nasdaq Dips Over 300 Points; PepsiCo Reports Weak Sales
Express News | Renalytix Shares Are Trading Higher After the Company Announced a Collaboration With the Steno Diabetes Center, Copenhagen, to Advance Translation of Precision Medicine Solutions for Patients With Diabetes and Chronic Kidney Disease
Express News | Renalytix Collaborates With Steno Diabetes Center, Cpenhagen, To Develop A Roadmap For Implementation Of KidneyIntelX, Marking First Expansion For KidneyIntelX Platform Beyond US
Renalytix AI Expands Kidney Health Platform to Europe
Renalytix AI Sees Major Stake Shift
Renalytix Requests Hearing With Nasdaq to Maintain Listing
Renalytix Fights Nasdaq Delisting With Strategic Plan, Trading Temporarily Safe
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
ADRs Close Lower; Renalytix Declines 29%
Renalytix to Appeal Nasdaq Delisting Over Non-compliance